Amicus Therapeutics, Inc. (NASDAQ: FOLD) is watching its shares drop on Tuesday after the company provided an update on its regulatory pathway for its Fabry Disease treatment. After the company had several collaborative discussions with the U.S. Food and Drug Administration (FDA), Amicus plans to collect additional data on gastrointestinal (GI) symptoms in Fabry patients who have an amenable mutation.
During its review of the briefing document submitted and in discussions with Amicus, the FDA acknowledged that significant unmet medical need exists in Fabry disease. The agency also indicated that kidney globotriaosylceramide (GL-3) is currently not considered a basis for an accelerated approval.
More than 50% of patients with Fabry disease report or show GI signs and symptoms, including diarrhea, abdominal pain, constipation, nausea, and vomiting. Amicus previously presented positive GI data in a completed Phase 3 randomized, placebo controlled Study 011 (FACETS) in treatment-na茂ve Fabry patients with amenable mutations.
Top 5 Medical Stocks To Buy Right Now: ManpowerGroup(MAN)
Advisors’ Opinion:
- [By Lisa Levin] Related TRST Earnings Scheduled For October 21, 2016 Major Accounting Changes Are Coming To The Financial Industry
Related MORN One Of The World's Most Powerful Women, Fidelity Personal Investing President Kathleen Murphy, To Tell Her Story At The Benzinga Global Fintech Awards The 2017 Benzinga Global Fintech Awards Will Include An 'Unprecedented Group' Of Judges Morningstar Packs Conference Lineup For Financial Advisors (Investor’s Business Daily) Companies Reporting Before The Bell
Rockwell Collins, Inc. (NYSE: COL) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.33 billion.
General Electric Company (NYSE: GE) is expected to report quarterly earnings at $0.17 per share on revenue of $26.46 billion.
Honeywell International Inc. (NYSE: HON) is estimated to report quarterly earnings at $1.60 per share on revenue of $9.32 billion.
Interpublic Group of Companies Inc (NYSE: IPG) is expected to report quarterly earnings at $0.03 per share on revenue of $1.76 billion.
Schlumberger Limited. (NYSE: SLB) is estimated to report quarterly earnings at $0.26 per share on revenue of $7.02 billion.
SunTrust Banks, Inc. (NYSE: STI) is expected to report quarterly earnings at $0.83 per share on revenue of $2.21 billion.
ManpowerGroup Inc. (NYSE: MAN) is projected to report quarterly earnings at $1.11 per share on revenue of $4.68 billion.
Kansas City Southern (NYSE: KSU) is estimated to report quarterly earnings at $1.15 per share on revenue of $593.82 million.
Stanley Black & Decker, Inc. (NYSE: SWK) is projected to report quarterly earnings at $1.19 per share on revenue of $2.74 billion.
WABCO Holdings Inc. (NYSE: WBC) is estimated to report quarterly earnings at $1.44 per share on revenue of $721.89 million. - [By Bryan Murphy]
Look out ManpowerGroup Inc. (NYSE:MAN). And Robert Half International Inc. (NYSE:RHI)? You may want to look over your shoulder as well. A young-and-hungry staffing solutions competitor named Staffing 360 Solutions Inc (NASDAQ:STAF) is coming on strong, and just proved it again today. Some of its preliminary fiscal Q2 numbers were reported today, and they extend what’s become a long-term growth streak.
The definition of a roll-up isn’t a hard and fast one, though even the broad brush strokes paint a pretty clear picture. Investopedia defines a roll-up (also known as a “roll up” or a “rollup”) a merger that occurs when investors (often private equity firms) buy up companies in the same market and merge them together. Roll-ups combine multiple small companies into something bigger and better to be able to enjoy economies of scale. Private equity firms use roll-ups to rationalize competition in crowded and/or fragmented markets and to combine companies with complementary capabilities into a full-service business.
It’s also the kind of strategy Staffing 360 Solutions is executing, with great success. For the fiscal quarter ending in November, Staffing 360 Solutions has pre-reported revenue of $47 million, and a gross profit of $8.1 million. Those figures are up 14% and 8%, respectively, year-over-year.
- [By Bryan Murphy]
Staffing agencies like Robert Half International Inc. (NYSE:RHI) and ManpowerGroup Inc. (NYSE:MAN) may want to look over their shoulder. Though both are bigger and more established, their size and the waning need for physical, human workers in an increasingly-digital and roboticized world ultimately works against both organizations. That paradigm shift doesn’t matter much to a young, up-coming-staffing agency called Staffing 360 Solutions Inc (NASDAQ:STAF) though. Indeed, the trend of computer-based everything leaves Staffing 360 Solutions in the proverbial cat-bird’s seat. Its fiscal Q2 numbers verify the company is in the right place at the right time.
Those numbers? Revenue of $47.1 million was up 14%, and gross profits of $8.1 million were higher by 8.4% on a year-over-year basis. Moreover, the net loss of $1.5 million was a marked improvement on the year-ago loss of $3.5 million, and the EBITDA of $1.4 million was about the same. Operating expenses fell from 22% of revenue a year earlier to only 17% last quarter, with more such progress on the way.
Perhaps most important, Staffing 360 Solutions saw organic growth of 7%, meaning the top line bumped up by that much not because of acquisitions, but because it’s existing divisions expanded their client base and billings by 7%.
And last quarter’s progress has been the norm for several quarters now.
While STAF is proving outpacing the growth from bigger names like ManpowerGroup and Robert Half International, it can’t come as a complete surprise. Staffing 360 Solutions is focused on the IT sliver of the staffing industry, connecting companies with the technology-skilled programmers, cybersecurity specialists, and computer networking personnel modern organizations increasingly need.
There are several data nuggets that point in the same direction, but perhaps none as telling as a recent conclusion from technology research outfit IDC speaks volumes. IDC believes that by the
Top 5 Medical Stocks To Buy Right Now: Novellus Systems Inc.(NVLS)
Advisors’ Opinion:
- [By Paul Ausick]
Nivalis Therapeutics Inc. (NASDAQ: NVLS) dropped 60% on Tuesday to post a new 52-week low of $2.50 after closing at $6.25 on Monday. The stock’s 52-week high is $9.45. Volume of about 4.2million was about 60 times the daily average of around 75,000 shares. The company reported a failed mid-stage trial on its treatment for cystic fibrosis.
- [By Lisa Levin]
Nivalis Therapeutics Inc (NASDAQ: NVLS) shares dropped 59 percent to $2.58 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.
- [By Chris Lange]
Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.
Top 5 Medical Stocks To Buy Right Now: RPX Corporation(RPXC)
Advisors’ Opinion:
- [By Travis Hoium]
Shares of risk management company RPX Corp. (NASDAQ:RPXC) popped as much as 15% in trading Wednesday after buyout rumors started to swirl in the market. At 2:55 p.m. EST, shares had settled down to an 11.2% gain on the day.
Top 5 Medical Stocks To Buy Right Now: Santander Consumer USA Holdings Inc.(SC)
Advisors’ Opinion:
- [By Jim Robertson]
On Friday, our Under the Radar Moversnewsletter suggested going long on small cap consumer financestock Santander Consumer USA Holdings (NYSE: SC):
- [By Wayne Duggan]
Height Financial Services analyst Edwin Groshans believes Credit Acceptance Corp, Santander Consumer USA Holdings Inc (NYSE: SC), Ally Financial Inc (NYSE: ALLY) and Capital One Financial Corp. (NYSE: COF).
Top 5 Medical Stocks To Buy Right Now: NCI Building Systems, Inc.(NCS)
Advisors’ Opinion:
- [By Scott Rubin]
Equity gainers on the day included Chico's FAS, Inc. (NYSE: CHS), which surged more than 12 percent on the day, and Himax Technologies (NASDAQ: HIMX), which climbed almost 9 percent in the wake of an afternoon rally. Losers included NCI Building Systems Inc. (NYSE: NCS), which fell 15 percent after earnings, and H&R Block inc (NYSE: HRB), which fell almost 11 percent on the day after its Q1 results.
- [By Lisa Levin]
NCI Building Systems Inc (NYSE: NCS) was down, falling around 14 percent to $15.27. NCI Building Systems reported Q3 adjusted earnings of $0.33 per share on revenue of $462.4 million.
- [By Monica Gerson]
NCI Building Systems Inc (NYSE: NCS) posted upbeat results for its second quarter on Tuesday. NCI Building Systems shares rose 1.24 percent to $16.30 in the after-hours trading session.
- [By Jim Robertson]
Yesterday, small cap NCI Building Systems (NYSE: NCS) sank 20.54% after the maker of metal products for the nonresidential building industry reported disappointing Q3 results and cut its sales outlook. NCI Building Systems is one of North America’s largest integrated manufacturers and marketers of coatings, components and metal buildings for the nonresidential building industry and is comprised of a family of companies operating manufacturing facilities across the United States, Canada, Mexico and China (with additional sales and distribution offices throughout the United States and Canada).
